PIK3CA Mutation CDx
Tissue & Plasma
Informing a new biomarker-driven strategy for HR+/HER2- advanced breast cancer
PIK3CA is the most commonly mutated gene in patients with HR+/HER2- advanced (aBC) or metastatic breast cancer (mBC). In fact, studies have shown up to 40% of patients with HR+/HER2- aBC may present with a PIK3CA mutation, and these patients may face an overall worse prognosis. Clinical guidelines recommend assessing for PIK3CA mutation as part of the initial mBC workup if the patient has recurrent/Stage IV (M1) disease, the tumor is HR+/HER2- and if considering therapy with alpelisib.
Testing with the FDA-approved PIK3CA Mutation CDx Test by either Tissue or Plasma can identify patients with a PIK3CA mutation who are eligible for PIQRAY® (alpelisib), alpha-specific PI3K inhibitor. Exclusively through NeoGenomics, the PIK3CA Mutation CDx Testing Program provides eligible patients access to testing at no cost.
Who is eligible for testing under the PIK3CA Mutation CDx Testing Program:
- Complete, sign and submit the PIK3CA Mutation CDx Test Request Form to NeoGenomics.
- Submit specimen sample (see specimen requirements). Primary or metastatic breast tumor specimens are acceptable. Decalcified specimens are not accepted.
- Contact NeoGenomics Client Services at 866.776.5907, option 3 or firstname.lastname@example.org if you have questions.
- Call NeoGenomics Client Services at 866.776.5907, option 3 to complete your prequalification call.
Please review our linked Resources for full details.
FAQ for Health Care Professionals
PIK3CA Testing for Advanced or Metastatic HR+/HER2- Breast Cancer with PIK3CA Mutation CDx at NeoGenomics Laboratories
Patients, please consult your medical care team to discuss whether you are a candidate for testing.
Mutations in the PIK3CA gene can act as cancer drivers and are found in ~40% of hormone receptor-positive (HR+) breast cancer cases. They are the most common mutations in HR+ breast cancer and have been associated with a poor prognosis.
Until 2019, there was no targeted therapy available for patients with advanced or metastatic HR+/HER2- breast cancer. PIQRAY® (alpelisib) is the first and only FDA-approved targeted therapy for patients with HR+/HER2- advanced or metastatic breast cancer who have progressed on endocrine therapy and whose tumors have a PIK3CA mutation. Only patients with a PIK3CA mutation are eligible for biomarker-driven therapy with alpelisib.
Yes, QIAGEN’s therascreen® PIK3CA RGQ PCR is the FDA-approved companion diagnostic test. NeoGenomics provides this test under the name PIK3CA Mutation CDx and it is available through an exclusive Companion Diagnostic Testing Program.
The Companion Diagnostic Testing Program is offered exclusively through NeoGenomics and is designed to ensure access to testing for patients eligible for alpelisib. Enrolled patients may receive one PIK3CA Mutation CDx by tissue and/or plasma (blood) test at no cost. Repeat tests for monitoring purposes are not accepted in this program. The Companion Diagnostic Testing Program is sponsored by Novartis Pharmaceuticals Corporation.
PIK3CA Mutation CDx – Plasma testing is appropriate when no primary or metastatic breast tumor tissue is available, or the only available tissue is from a tumor in the bone and therefore unsuitable for molecular testing. Tissue is the recommended specimen type in all other cases.
Clients who require plasma testing for patients with available tissue specimens may order plasma testing concurrently with tissue testing, or plasma testing followed by tissue testing if the plasma result is negative. The Companion Diagnostic Testing Program will cover testing for one such plasma and tissue specimen pair.
The ordering health care provider must complete and sign the appropriate PIK3CA Mutation CDx Test Request Form (for either Tissue or Plasma) and submit it to NeoGenomics, or complete the information and attestation in NeoGenomics’ online ordering system. Completion of this form is required and submission also enrolls the patient in the Companion Diagnostic Testing Program.
The Test Request Form for Tissue is available here. If tests in addition to PIK3CA Mutation CDx are required on the submitted tissue specimen, please also complete a separate standard, printed NeoGenomics test requisition or create a new accession in online ordering.
The Test request Form for Plasma is available directly from Client Services at 866-776-5907, option 3, after verbal review of specimen processing requirements.
NeoGenomics offers PIK3CA testing on formalin-fixed paraffin-embedded (FFPE) tumor resection or biopsy samples. Breast tumor tissue (either primary or metastatic) is required; non-breast tumors are not accepted for this test. The paraffin block is preferred. Alternatively, send 1 H&E slide plus 6-12 unstained slides for core needle biopsy (or 5-10 slides for resection) cut at 5 microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives or send decalcified specimens.
Requirements for collection, processing, and shipping plasma samples are very precise to maximize detection of circulating tumor DNA (ctDNA) in the patient’s plasma. NeoGenomics will provide a custom shipping container, collection tubes, and detailed instructions after telephone review and prequalification of their account. Requirements include:
- Processing of blood specimens within 4 hours of collection
- High-speed centrifuge and ability to transfer plasma to new tubes
- Low-temperature freezer (-70◦C to -90◦C)
- Access to dry ice for shipment to NeoGenomics
Please call Client services at 866-776-5907, option 3, to prequalify before scheduling your patient’s blood draw.
The test is intended to identify PIK3CA mutation in HR+/HER2- male or post-menopausal female breast cancer patients with advanced or metastatic disease that progressed on or after endocrine therapy. Testing is appropriate when patients present with metastases. Tissue testing is preferred over plasma testing.
Overall, there is a chance of approximately 80-90% that a plasma sample result will be negative. About 60% of results are true negatives as the PIK3CA mutation frequency in tissue is approximately 40%. Plasma specimens tested in the SOLAR-1 study showed correlation with mutation-positive paired tumor specimens in approximately 55% of cases. Other studies support specimen handling and low or absent tumor DNA shedding as significant contributors to discrepancies between positive tissue and negative plasma status.
The low expected positive rate in plasma reinforces the importance of testing tissue whenever tissue is available.
Participation in the Companion Diagnostic Testing Program is available to patients whose tumors are IHC positive for either or both estrogen receptor (ER) and progesterone receptor (PgR or PR) AND negative for HER2 by IHC, ISH, or FISH.
PIK3CA Mutation CDx runs on the QIAGEN RotorGene Q MDx platform using the therascreen® PIK3CA RGQ PCR Kit. This is a real-time qualitative PCR assay for the detection of 11 mutations in the PIK3CA gene using genomic DNA extracted from FFPE breast tumor tissue or DNA extracted from cell-free peripheral blood plasma. Mutations detected are in exon 7 (C420R), exon 9 (E542K, E545A, E545D [c.1635G>T only], E545G, E545K, Q546E, Q546R), and exon 20 (H1047L, H1047R, H1047Y).
Results are typically ready in 7 days from the time the specimen is received at NeoGenomics lab and will be sent to the ordering physician’s office or laboratory by their preferred method of delivery. Please add at least 6 days if NeoGenomics is retrieving tissue from another location.
No patient, health care program, or beneficiary shall be billed for this mutation test. If you should receive a bill, please contact the NeoGenomics Billing Department at 866-776-5907, option 2.
- therascreen® PIK3CA RGQ PCR [package insert]. Hilden, Germany: QIAGEN; document ID coming soon
- PIQRAY® (alpelisib) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; May 2019.
- Andre F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380(20):1929-1940.
- LoRusso PM. Inhibition of the PI3K/AKT/mTOR pathway in solid tumors. J Clin Oncol. 2016;34(31):3803-3815.
- Lee JJX, Loh K, Yap Y-S. PI3K/Akt/mTOR inhibitors in breast cancer. Cancer Biol Med. 2015;12(4):342-354.
- Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer. 2015;15(1):7-24.
- Sabine VS, Crozier C, Brookes CL, et al. Mutational analysis of PI3K/AKT signaling pathway in Tamoxifen Exemestane Adjuvant Multinational pathology study. J Clin Oncol. 2014;32(27):2951-2958.
- Aleskandarany MA, Rakha EA, Ahmed MA, et al. PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis. Breast Cancer Res Treat. 2010;122(1):45-53.
- Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24.
- Lippi G, Chance JJ, Church S, et al. Preanalytical quality improvement: from dream to reality. Clin Chem Lab Med. 2011;49(7):1113-1126.